Slide 1: ASX cover letter: Presentation to Investors
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 May 2015 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (11 pages by email) Dear Madam PRESENTATION TO INVESTORS I attach a Pow
Slide 2: Biotron Limited (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Mid-‐Clinical Stage An=viral Drug Development Company Dr Michelle Miller Managing Director Broker Meet Biotech +61 412 313329 mmiller@biotron.com.au May 2015 www.biotron.com.au
Slide 3: Forward Looking Statements
Forward Looking Statements This presenta6on may contain forward-‐looking statements with respect to the financial condi6on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec6ves of its management. These statements are statements tha
Slide 4: Biotron Snapshot
Biotron Snapshot • Mid-clinical stage antiviral drug development company • New mode-of-action, first-in-class small molecule drugs • Phase 2 clinical programs for Hepatitis C virus (HCV) and HIV • BIT225 has demonstrated clinical activity • Seven clinical trials completed; one in progress • Headquar
Slide 5: Biotron - Advanced Pipeline
Biotron -‐ Advanced Pipeline INDICATION COMPOUND DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Hep C BIT225 HIV/Hep C BIT225 HIV BIT225 Next genera=on -‐ BIT314 HCV Dengue Leads Slide 2
Slide 6: BIT225 – New Class of HCV Drug with Proven Clinical Track Record
BIT225 – New Class of HCV Drug with Proven Clinical Track Record ü Over 180 people dosed with BIT225 ü Posi6ve data recorded in all trials POLYMERASE/PROTEASE INHIBITORS e.g. Sovaldi/ Simeprevir ü Only one of its class (p7 inhibitor) in clinical trials BIT225 -‐ ASSEMBLY/ BUDDING INHIBITOR ü In
Slide 7: Large and Growing Global Market for Hepatitis C
Large and Growing Global Market for Hepa==s C • Forecast to grow to over $19bn by 2016 • 180 million infected worldwide (3% world popula6on) • ~3 to 5 million in US & 30 million in China • New drugs have demonstrated significant pricing power • Gilead’s Sovaldi (Sofosbuvir) at US$84,000 for a 12 week
Slide 8: HIV – Towards a Cure
HIV – Towards a Cure • Infec6on rates at 20 year high • Phase 2a trial showed BIT225 anacks HIV in macrophage cells in • Over 1.1 million people living with HIV in the USA; vivo, paralleling in vitro studies 1 in 6 unaware of diagnosis • Poten6al benefits on immune aging and HIV-‐associated demen6a
Slide 9: Investment Proposition
Investment Proposi=on • HCV and HIV are high growth, mul6-‐billion dollar markets • Treatment gaps remain • BIT225 is a novel approach with demonstrated promising efficacy in Phase 2a/2 clinical trials • Represents a new class of direct-‐ac6ng HCV drugs • Poten6al to fill significant HCV treatment gap
Slide 10: Outlook for 2015
Outlook for 2015 • Complete BIT225-‐008 HCV trial currently in progress • Preliminary interim data expected mid-‐2015 • Inves6ga6onal New Drug applica6on(s) (INDs) • Engaged with FDA -‐ pre-‐IND consulta6on HCV combina6on trial with DAA • File IND applica6on(s) mid-‐2015 • Currently comple6ng s
Slide 11: Financial Information
Financial Informa=on Key Financial Metrics 12 Month Share Price Performance Ticker Code ASX: BIT Share Price (27 May 2015) A $0.125 Ticker Code ASX: BIT Market cap A $32 million Share Price (15 Sept 2014) A $0.115 12 Month Trading Range A $0.0864 – 0.1832 Shares Outstanding 279 million Market cap A